Viewpoint |

Neurosteroids as Therapeutic Leads in Psychiatry

Charles F. Zorumski, MD1,2,3; Steven Mennerick, PhD1,2,3
[+] Author Affiliations
1Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
2Department of Neurobiology, Washington University School of Medicine, St Louis, Missouri
3The Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St Louis, Missouri
JAMA Psychiatry. 2013;70(7):659-660. doi:10.1001/jamapsychiatry.2013.245.
Text Size: A A A
Published online


Considerable progress has been made in understanding how neural circuits contribute to mental processing and psychiatric disorders. This research has highlighted the importance of network dysfunction, particularly changes in the balance between excitatory and inhibitory transmission within and across brain regions that underlie cognition, emotion, and motivation. Despite progress, the development of new and more effective treatments for psychiatric disorders has lagged considerably, and present pharmacological treatments represent incremental advances over agents introduced decades ago. One approach for identifying novel treatments has involved studies of neuronal stress responses and how these responses are modulated based on the role that stress plays in psychiatric disorders. In this overview, we describe cholesterol-derived agents (called neurosteroids) that are generated endogenously in the brain and that are important modulators of neuronal stress reactions.1 We highlight the potential of these agents as targets for therapeutic drug development in several neuropsychiatric illnesses.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles